{"cluster": 50, "subcluster": 45, "abstract_summ": "One of the world\u2019s best hopes for treating COVID-19 \u2014 a compound called remdesivir \u2014 has been authorized as a therapy against the disease On 1 May, the US Food and Drug Administration (FDA) granted an \u2018emergency-use authorization\u2019 for clinicians to use the drug, which is administered intravenously, in hospitals for people with severe COVID-19As scientists consider SARS-CoV-2 vaccine design, we discuss problems that may be encountered and how to tackle them by what we term \u201crational vaccine design.Nearly 100 years since it was first used in humans as a vaccine for tuberculosis, Bacillus Calmette\u2013Gu\u00e9rin (BCG) has been suggested as a possible agent to prevent coronavirus disease 2019 (COVID-19).This first International Alliance for Biological Standardization Covid-19 webinar brought together a broad range of international stakeholders, including academia, regulators, funders and industry, with a considerable delegation from low- and middle-income countries, to discuss the virology, epidemiology and immunology of, and the vaccine development for SARS-CoV-2.For over a century, transfusion of convalescent plasma from recovered individuals has been tried as a therapeutic approach when a novel pathogen emerges.A life-threatening, emerging respiratory disease called Coronavirus Disease 2019 (COVID-19) 26 originated in the city of Wuhan in China's Hubei province in December, 2019 and has been classified as 27 an international pandemic by the World Health Organization.\u2026.TheTherefore, in this article, new potential COVID-19 therapies are briefly reviewed.", "title_summ": "Convalescent Plasma to Treat COVID-19: Chinese Strategy and ExperiencesPotential Treatments for COVID-19; a Narrative Literature ReviewSARS-CoV-2: Virology, epidemiology, immunology and vaccine developmentPassive antibody therapy in COVID-19Could BCG be used to protect against COVID-19?COVID-19 vaccines: neutralizing antibodies and the alum advantageOf chloroquine and COVID-19Reduction of coronavirus burden with mass azithromycin distributionCOVID-19 vaccine design: the Janus face of immune enhancementCoronavirus drug, water warning and virus-research funding.Accelerating drug development through repurposed FDA approved drugs for COVID-19: speed is important, not haste.Rational Vaccine Design in the Time of COVID-19", "title_abstract_phrases": "One of the world\u2019s best hopes for treating COVID-19 \u2014 a compound called remdesivir \u2014 has been authorized as a therapy against the disease On 1 May, the US Food and Drug Administration (FDA) granted an \u2018emergency-use authorization\u2019 for clinicians to use the drug, which is administered intravenously, in hospitals for people with severe COVID-19Rational Vaccine Design in the Time of COVID-19As scientists consider SARS-CoV-2 vaccine design, we discuss problems that may be encountered and how to tackle them by what we term \u201crational vaccine design.We found that the respiratory burden of non-SARS coronaviruses was decreased with azithromycin distributions.Could BCG be used to protect against COVID-19?Nearly 100 years since it was first used in humans as a vaccine for tuberculosis, Bacillus Calmette\u2013Gu\u00e9rin (BCG) has been suggested as a possible agent to prevent coronavirus disease 2019 (COVID-19).A life-threatening, emerging respiratory disease called Coronavirus Disease 2019 (COVID-19) 26 originated in the city of Wuhan in China's Hubei province in December, 2019 and has been classified as 27 an international pandemic by the World Health Organization.\u2026.Convalescent Plasma to Treat COVID-19: Chinese Strategy and ExperiencesThe COVID-19 is currently spreading around the world, which has posed significant threats to global health and economy.Accelerating drug development through repurposed FDA approved drugs for COVID-19: speed is important, not haste."}